Objectives: The aim of this study was to examine tumor-infiltrating lymphocytes (TILs) and their prognostic value in patients with pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy. + TILs were an independent prognostic factor for disease-free survival (hazard ratio, 0.49; 95% confidence interval, 0.30-0.81; P = 0.005) and OS (hazard ratio, 0.54; 95% confidence interval, 0.33-0.89; P = 0.02).
, and FOXP3 + lymphocytes were examined by immunohistochemistry using a computer-assisted quantitative analysis in 136 PDAC patients who received neoadjuvant therapy and pancreaticoduodenectomy. The results were correlated with clinicopathological parameters and survival.
Results: High CD4 + TILs in treated PDAC were associated with high CD8 + TILs (P = 0.003), differentiation (P = 0.04), and a lower frequency of recurrence (P = 0.02). Patients with high CD4 + TILs had longer disease-free survival and overall survival (OS) than did patients with low CD4 + TILs (P < 0.01). The median OS of patients with a high CD8 + / FOXP3 + lymphocyte ratio (39.5 [standard deviation, 6 .1] months) was longer than that of patients with a low CD8 + /FOXP3 + lymphocyte ratio (28.3 [standard deviation, 2.3] months; P = 0.01). In multivariate analysis, high CD4 + TILs were an independent prognostic factor for disease-free survival (hazard ratio, 0.49; 95% confidence interval, 0.30-0.81; P = 0.005) and OS (hazard ratio, 0.54; 95% confidence interval, 0.33-0.89; P = 0.02).
Conclusions: High level of CD4
+ lymphocytes is associated with tumor differentiation and lower recurrence and is an independent prognostic factor for survival in PDAC patients treated with neoadjuvant therapy.
Key Words: CD4, CD8, FOXP3, pancreatic cancer, prognosis, tumor-infiltrating lymphocytes (Pancreas 2017;46: 1180-1187) P ancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy and the fourth leading cause of cancer-related death in the United States. 1 The lack of effective conventional therapies for patients with the disease has prompted researchers to investigate novel treatments and obtain a better understanding of PDAC biology and drug resistance. 2, 3 The tumor microenvironment plays an important role in the biology of cancers. Among the components of the tumor microenvironment, tumor-infiltrating lymphocytes (TILs) have been shown to have prognostic value in patients with a wide variety of cancers. [4] [5] [6] [7] [8] [9] Tumor-infiltrating lymphocytes are composed of a heterogeneous population of lymphocytes that promote either tumor immunity or tumor pathogenesis. 10 12 reported that PDAC patients with high numbers of CD8 + TILs and CD4 + TILs had a significantly longer overall survival (OS) rate than did patients with low numbers of TILs. Other studies have shown that in PDAC patients a high density of FOXP3 + Tregs, which are believed to help suppress T-cell-mediated immune responses and effective antitumor immune responses, is correlated with a high risk of lymph node metastasis and with poor prognosis. [13] [14] [15] More PDAC patients who are potential candidates for pancreaticoduodenectomy (PD) now receive neoadjuvant chemotherapy prior to the surgery. Increasing evidence in breast cancer suggests that chemotherapeutic agents, which are generally considered to be immunosuppressive, can elicit antitumor immunological responses that enhance the efficacy of the treatment and improve patient survival. 16, 17 It has also been shown that the postchemotherapy TIL status of residual triple-negative or HER2-positive breast cancer has prognostic value. [18] [19] [20] It has been suggested that chemotherapeutic agents may exert their immunostimulatory effects by inducing immunogenic tumor cell death directly, mitigating immunosuppressive mechanisms, creating lymphopenia and an immunogenic milieu, and/or sensitizing tumor cells to immune destruction. 16, [21] [22] [23] [24] However, few studies have investigated the composition of TILs in PDAC after neoadjuvant chemotherapy. 25 The role of TILs in PDAC after neoadjuvant therapy and their effect on patient prognosis remain unclear. 
MATERIALS AND METHODS

Patient Population
The institutional review board of The University of Texas MD Anderson Cancer Center approved this study. Our study population consists of 136 PDAC patients (83 men and 53 women) who underwent neoadjuvant chemotherapy followed by PD between 1999 and 2007. The patients' clinicopathological data, including sex, age, tumor differentiation, histologic subtype, T stage, American Joint Committee on Cancer stage, and lymph node status, and their follow-up data were extracted from the prospectively maintained database at the Department of Surgical Oncology and validated by reviewing medical records. If necessary, patient deaths were confirmed by review of the US Social Security Death Index. The patients' median age was 63.5 years (range, 42.1-84.2 years). Two pathologists separately reviewed patients' archived tumor specimens for histologic type, differentiation, stage, margin status, regression grade, and lymph node metastasis.
Tissue Microarray Construction
We used a tissue microarrayer (Beecher Instruments, Sun Prairie, Wis) to construct tissue microarrays from formalinfixed, paraffin-embedded blocks of archived PDAC specimens as described previously. 26 Briefly, a gastrointestinal pathologist (N.H.) reviewed matched hematoxylin-eosin-stained slides to select the best representative tumor region for each case. Three 1.0-mm tissue cores from each selected representative tumor region were used for tissue microarray construction.
Immunohistochemical Analysis for CD4, CD8, and FOXP3
Immunohistochemistry for CD4, CD8, and FOXP3 was performed on 4-μm unstained sections from the tissue microarray blocks using primary mouse monoclonal antibodies against CD4 (1:25 dilution, SP35; Cell Marque, Rocklin, Calif ), CD8 (1:20 dilution from predilute, C8/144B; Thermo Scientific, Fremont, Calif ), and FOXP3 (1:50 dilution, clone 206D; BioLegend, San Diego, Calif ). The tissue sections were deparaffinized and placed in a 100°C steamer containing 20 mmol citrate buffer (pH 6.0) for 5 minutes for antigen retrieval. The sections were then incubated with the primary antibody at 35°C for 15 minutes, immersed in 3.0% hydrogen peroxidase at 35°C for 5 minutes to block endogenous peroxide activity, immersed in polymer enhancer for 8 minutes, and then incubated with secondary polyhorseradish peroxidase anti-mouse/anti-rabbit immunoglobulin G at 35°C for 8 minutes. The 3,3′-diaminobenzidine was used as a chromogen. Hematoxylin was used for counterstaining. 
Statistical Analysis
We used the χ 2 or Fisher's exact test to compare categorical data. Overall survival was defined as the time from the date of PDAC diagnosis to the date of death or the date of last followup if death did not occur. Disease-free survival (DFS) duration was defined as the time from the date of surgery to the date of first recurrence in patients with recurrence or to the date of last followup in patients without recurrence. Survival curves were constructed using the Kaplan-Meier method, and the log-rank test was used to evaluate the statistical significance of difference in survival. Univariate and multivariate Cox regression analyses were used to assess the prognostic significance of clinicopathological variables. We used the SPSS Statistics for Windows (version 22; IBM SPSS Inc, Armonk, NY) to perform all statistical analyses. We used a 2-sided significance level of 0.05 for all statistical analyses. + TIL count was associated with a higher recurrence or distant metastasis rate compared with that of patients whose tumors had a low FOXP3 + TILs (P = 0.046, Table 1 ).
RESULTS
Tumor
Survival Analysis
The median follow-up duration after surgery was 32.5 months (range, 7.6-172.8 months) for all patients and 107.1 months (range, 9.4-172.8 months) for the patients who remained alive at the end of study. Patients whose tumors had high CD4 + TILs had longer DFS and OS than did patients whose tumors had low CD4 + TILs (Fig. 2  and Table 2 Table 2 ). The multivariate analysis revealed that a high CD4 + TIL count, lymph node metastasis, and tumor regression grade were independent prognostic factors for DFS and OS (Table 3 ). The correlation of CD8 + /FOXP3 + lymphocyte ratio with either DFS or OS was also significant by multivariate analysis (P > 0.05).
DISCUSSION
Several studies have investigated the role of TILs and their correlation with clinical outcomes in PDAC patients. Fukunaga et al 12 showed that the 5-year OS rate of patients with CD8 + tumors (tumors with an average CD8 + T-cell count of ≥100 for 5 microscopic fields at Â400 magnification) was higher than that of patients with CD8
− tumors. They also reported that the OS rate of patients with CD4
+ tumors (tumors with an average CD4 + T-cell count of ≥20 for 5 microscopic fields at Â400 magnification) was higher than that of patients with CD4 − tumors, but the difference was not statistically significant. They showed that the combined CD8 + /CD4 + phenotype was an independent prognostic factor for survival, although neither CD8 + nor CD4 + tumor status alone was an independent predictor of survival by multivariate analysis. They thus concluded that the presence of both CD4 + and CD8
+ T-cells is crucial to effective tumor immunity in PDAC. 12 Tewari et al 31 evaluated the prognostic significance of CD3 + , CD8 + , and CD20 + TILs in 81 PDAC patients and found an association between high levels of CD3 + and CD20 + TILs and higher survival rates. In another study, Ino et al 32 found that patients with a high CD4 + T-cell count, high CD8 + T-cell count, and low Treg count (defined as values higher and lower than the median for tumor-infiltrating immune cells) had longer survival than did those with a low CD4 + T-cell count, low CD8 + T-cell count, and high Treg count. A growing body of evidence suggests that the TIL status in the residual tumor after neoadjuvant chemotherapy can predict clinical outcomes of breast cancer patients. 33, 34 However, the prognostic significance of TILs in patients with PDAC who received neoadjuvant therapies and PD is not clear. In this study, we examined 136 such patients and found that a high CD4 + TIL count is an independent prognostic factor for DFS and OS in PDAC patients who received neoadjuvant therapy and PD. In addition, we also showed that a high CD8 + /FOXP3 + lymphocyte ratio correlated with better clinical outcomes in such patients. In contrast to the previous studies, we did not find significant correlation between CD8 + TILs and survival or other clinicopathological features. This may be due to the fact that all patients in this study received neoadjuvant therapy before PD, which is different from previous studies of TILs in PDAC samples from patients who received no neoadjuvant therapy. It is possible that neoadjuvant therapy may suppress CD8 + TILs and therefore does not impact survival in our study population. In one of the few studies that specifically evaluated the composition of TILs in PDAC patients who had received adjuvant chemoradioimmunotherapy, Karakhanova 
